Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80880 |
Name | diffuse glioma, H3 G34 mutant |
Definition | A histone mutated tumor that has_material_basis_in mutations in codon 34 of the H3 histone family 3A protein. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma histone mutated tumor diffuse glioma, H3 G34 mutant |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Completed | USA | 0 |
NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT05457959 | Phase I | Nivolumab + Poly ICLC Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Nivolumab + Poly ICLC | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | Not yet recruiting | USA | 0 |
NCT06342908 | Phase I | Neoantigen-targeted ppDC Poly ICLC | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | Not yet recruiting | 0 |